人参皂苷Rg3联合新辅助放化疗对胃癌组织VEGF、MTA1蛋白表达及预后的影响

摘要

[Objective]To study the effect of ginsenoside Rg3 combined with neoadjuvant chemoradiotherapy on the expression of VEGF and MTA1 protein in gastric cancer tissues,immune function and prognosis.[Methods]A total of 84 patients with gastric cancer were randomized into the control group and the treatment group according to different methods of treatment.The control group was given neoadjuvant concurrent radiotherapy and chemotherapy before operation,while the experimental group was treated with ginsenoside Rg3 in addition to concurrent radiotherapy and chemotherapy.The changes of expression of VEGF and MTA1 protein,immune function and prognosis were compared between the two groups before and after treatment.[Results]The RO resection rate and the total effective rate of the treatment group were higher than those of the control group (P ＜0.05).Compared to pretreatment,the positive rates of VEGF and MTA1 post-treatment in both groups were significantly reduced (P ＜0.05),and the decrease in the experimental group was significantly greater than that in the control group (P ＜0.05).After treatment,the percentage of CD3+ and CD4+,CD4+/CD8+ value and conversion rate of T cells in the experimental group increased significantly compared to the control group (P ＜0.05),while the percentage of CD8+ decreased significantly (P ＜ 0.05).There was no significant difference in the incidence of bone marrow suppression between the two groups (P ＞0.05).The recurrence rate in the experimental group was low than the control group (P ＜0.05).The 1-year,3-year and 5-year survival rates of the experimental group were higher than those of the control group (P ＜0.05).[Conclusion]Ginsenoside Rg3 combined with neoadjuvant chemoradiotherapy in patients with gastric cancer shows higher RO resection rate.It can significantly lower the expression of VEGF and MTA1,improve body immunity,reduce recurrence rate,and increase the survival rate of patients.The effect is significant in clinical application.%[目的]探讨人参皂苷Rg3联合新辅助放化疗对胃癌组织血管内表皮生长因子(VEGF)和肿瘤转移相关蛋白1(MTA1)表达、免疫功能及预后的影响.[方法]84例胃癌患者依据治疗方式的不同,随机分为两组,对照组术前给予新辅助同步放化疗治疗,治疗组在对照组治疗的基础上,同时服用人参皂苷Rg3治疗.比较两组治疗前后VEGF、MTA1蛋白表达,免疫功能变化及预后.[结果]治疗组根治性切除(RO)切除率,近期治疗总有效率均高于对照组(P＜0.05);与治疗前比较,两组VEGF和MTA1阳性率均显著降低(P＜0.05),且治疗组降低程度显著高于对照组(P＜0.05);治疗后治疗组患者CD3+、CD4+百分比、CD4+/CD8+值、T细胞转化率均显著上升(P＜0.05),CD8+百分比显著下降(P＜0.05),与对照组比较差异显著(P＜0.05);两组骨髓抑制发生率相比较差异无显著性(P＞0.05);治疗组复发率明显低于对照组71.4％(P＜0.05);治疗组1、3、5年存活率高于对照组(P＜0.05).[结论]人参皂苷Rg3联合新辅助放化疗治疗胃癌患者,RO切除率高,可显著降低患者VEGF和MTA1阳性率,提高患者免疫,降低肿瘤复发率,提高患者生存率,效果显著,具有重要临床意义.